865-405-1000 ext. 827

A long-acting injectable formulation of ViiV’s cabotegravir and Janssen’s Edurant (rilpivirine), dosed every four or eight weeks, is safe and generally well tolerated and suppresses HIV as well as a daily oral regimen in an ongoing trial.  The companies intend to start Phase III trials of long-acting cabotegravir/Edurant, dosed every eight weeks, later this year. If this research is successful, the treatment will likely hit the market in 2019.

Read more of this article from POZ.com here: 8week-injectable-article